succinobucol has been researched along with 2-keto-4-methylvalerate in 1 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (2-keto-4-methylvalerate) | Trials (2-keto-4-methylvalerate) | Recent Studies (post-2010) (2-keto-4-methylvalerate) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 738 | 52 | 73 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, JD; Cole, BK; Crim, WS; Kunsch, C; Mirmira, RG; Nadler, JL; Nunemaker, CS; Trace, AP; Wu, R | 1 |
1 other study(ies) available for succinobucol and 2-keto-4-methylvalerate
| Article | Year |
|---|---|
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxidants; Calcium; Cell Death; Cytokines; Diazoxide; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Keto Acids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Potassium Channels; Probucol; Tolbutamide | 2010 |